Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression

Lignende værker

• Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?
  af: Piotrowska, Zofia, et al.
  Udgivet: (2015)
• Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.
  af: Piotrowska, Zofia, et al.
  Udgivet: (2018)
• Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers
  af: Khandekar, Melin J., et al.
  Udgivet: (2018)
• First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
  af: Ricciuti, Biagio, et al.
  Udgivet: (2018)
• Phase IB study of osimertinib in combination with navitoclax in EGFR-mutant NSCLC following resistance to initial EGFR therapy (ETCTN 9903)
  af: Bertino, Erin M., et al.
  Udgivet: (2020)